Abstract
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Current Clinical Pharmacology
Title: Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Volume: 5 Issue: 3
Author(s): Otto Metzger-Filho, Camilo Moulin and Ahmad Awada
Affiliation:
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Abstract: Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Export Options
About this article
Cite this article as:
Metzger-Filho Otto, Moulin Camilo and Awada Ahmad, Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498716
DOI https://dx.doi.org/10.2174/157488410791498716 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment
Current Pharmaceutical Design Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer
Current Chemical Biology The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study
Letters in Drug Design & Discovery Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes
Current Medicinal Chemistry Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism
MicroRNA Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery In Silico Studies towards Enhancing the Anticancer Activity of Phytochemical Phloretin Against Cancer Drug Targets
Current Drug Therapy Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Gemcitabine Interacts with Carbonate Apatite with Concomitant Reduction in Particle Diameter and Enhancement of Cytotoxicity in Breast Cancer Cells
Current Drug Delivery